Last reviewed · How we verify
Rescue medications for sacituzumab tirumotecan
Rescue medications for sacituzumab tirumotecan is a antibody-drug conjugate Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently in Phase 3 development for Metastatic triple-negative breast cancer, Metastatic non-small cell lung cancer.
Sacituzumab govitecan is an antibody-drug conjugate that targets Trop-2, delivering a cytotoxic payload to cancer cells.
Sacituzumab govitecan is an antibody-drug conjugate that targets Trop-2, delivering a cytotoxic payload to cancer cells. Used for Metastatic triple-negative breast cancer, Metastatic non-small cell lung cancer.
At a glance
| Generic name | Rescue medications for sacituzumab tirumotecan |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | antibody-drug conjugate |
| Target | Trop-2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
The antibody binds to Trop-2 on the surface of tumor cells, facilitating internalization of the conjugate and release of the cytotoxic agent SN-38, which inhibits DNA replication and leads to cell death.
Approved indications
- Metastatic triple-negative breast cancer
- Metastatic non-small cell lung cancer
Common side effects
- Neutropenia
- Diarrhea
- Nausea
Key clinical trials
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) (PHASE3)
- A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) (PHASE3)
- A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) (PHASE3)
- A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) (PHASE3)
- Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) (PHASE1, PHASE2)
- A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rescue medications for sacituzumab tirumotecan CI brief — competitive landscape report
- Rescue medications for sacituzumab tirumotecan updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI
Frequently asked questions about Rescue medications for sacituzumab tirumotecan
What is Rescue medications for sacituzumab tirumotecan?
How does Rescue medications for sacituzumab tirumotecan work?
What is Rescue medications for sacituzumab tirumotecan used for?
Who makes Rescue medications for sacituzumab tirumotecan?
What drug class is Rescue medications for sacituzumab tirumotecan in?
What development phase is Rescue medications for sacituzumab tirumotecan in?
What are the side effects of Rescue medications for sacituzumab tirumotecan?
What does Rescue medications for sacituzumab tirumotecan target?
Related
- Drug class: All antibody-drug conjugate drugs
- Target: All drugs targeting Trop-2
- Manufacturer: Merck Sharp & Dohme LLC — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Metastatic triple-negative breast cancer
- Indication: Drugs for Metastatic non-small cell lung cancer
- Compare: Rescue medications for sacituzumab tirumotecan vs similar drugs
- Pricing: Rescue medications for sacituzumab tirumotecan cost, discount & access